Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05), Zacks reports.
Oric Pharmaceuticals Stock Down 4.3%
Shares of ORIC stock traded down $0.34 on Monday, reaching $7.52. 1,196,157 shares of the stock were exchanged, compared to its average volume of 1,714,194. The stock has a market cap of $779.47 million, a P/E ratio of -5.57 and a beta of 1.23. The firm has a 50 day moving average of $11.56 and a two-hundred day moving average of $11.01. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.68.
Insider Transactions at Oric Pharmaceuticals
In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 14,000 shares of the company’s stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at $944,772.84. This represents a 16.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock worth $1,432,952 over the last ninety days. 5.70% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of research firms have recently weighed in on ORIC. Leerink Partners began coverage on shares of Oric Pharmaceuticals in a research report on Monday, October 5th. They issued an “outperform” rating and a $26.00 price objective for the company. BTIG Research restated a “buy” rating and set a $26.00 target price on shares of Oric Pharmaceuticals in a research report on Wednesday, October 28th. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. JPMorgan Chase & Co. lifted their target price on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Finally, Stifel Nicolaus boosted their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a report on Monday, October 26th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.25.
Read Our Latest Stock Report on ORIC
Oric Pharmaceuticals Company Profile
Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.
See Also
- Five stocks we like better than Oric Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
